Inactive Instrument

ValiRx Plc Share Price London S.E.

GB00B23N9136

Biotechnology & Medical Research

End-of-day quote London S.E.
- ^GBX	-

10/08	ValiRx subsidiary Cytolytix nears "significant" European patent win	AN
10/08	ValiRx Unit Receives Intention to Grant European Patent for Anti-Cancer Peptide	MT

ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	20.46L 27.75L 23.91L 22.42L 38.55L 27Cr 38.68L 2.66Cr 1.04Cr 13Cr 1.04Cr 1.02Cr 44Cr	P/E 2024	-0.53x	P/E 2025	-0.62x
Enterprise Value	12.56L 17.03L 14.68L 13.76L 23.67L 16Cr 23.74L 1.63Cr 63.7L 8.22Cr 63.95L 62.56L 27Cr	EV / Sales 2024	2,72,64,249x	EV / Sales 2025	5,41,21,446x
Free-Float	91.05%	Yield 2024 *	-	Yield 2025	-

10/08	ValiRx subsidiary Cytolytix nears "significant" European patent win	AN
10/08	ValiRx Unit Receives Intention to Grant European Patent for Anti-Cancer Peptide	MT
10/08	Cytolytix Limited Receives Notification of Intention to Grant European Patent for Polyleucine-Based Peptides as Anti-Cancer Agents	CI
18/07	Valirx plc Announces Termination of Catherine Jane Tralau-Stewart from Director Role, Effective July 17, 2026	CI
23/06	EARNINGS AND TRADING: ValiRx profit slides; Ukrproduct loss narrows	AN
22/06	Maintel fundraising completes; ValiRx ends deal	AN
22/06	Valirx plc Announces the Resignation of Tralau-Stewart as Chair of the Advisory Board and Non-Executive Director	CI
22/06	ValiRx plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
22/06	Earnings Flash (VAL.L) ValiRx Plc Reports FY25 Revenue GBP31,372	MT
02/06	ValiRx Completes Oncology Assets Evaluation Deal with Stingray Bio	MT
28/05	ValiRx subsidiary Cytolytix granted "core" European patent	AN
27/05	ValiRx Unit Wins European Patent for Anti-Cancer Peptide Patent	MT
21/05	ValiRx Raises Funds via Retail Offering	MT

24/25/24	ValiRx PLC - Director Disclosure Update	AQ
19/24/19	ValiRx plc - Inaphaea Evaluation and Commercial Use Agreement	AQ
06/23/06	ValiRx strikes deal with Ambrose Healthcare to license late-stage cancer treatment	AQ
01/23/01	ValiRx signals launch of new strategy with Nottingham laboratories	AQ
16/22/16	ValiRx appoints preclinical project manager to drive development of triple breast cancer treatment	AQ

Manager	Title	Age	Since
Mark Eccleston CEO	Chief Executive Officer	55	12/08/2024
Gerald Desler DFI	Director of Finance/CFO	81	-
Michelle Barnard CTO	Chief Tech/Sci/R&D Officer	-	27/03/2025

Director	Title	Age	Since
Gerald Desler BRD	Director/Board Member	81	01/09/2006
Martin Gouldstone CHM	Chairman	60	25/07/2024
Mark Eccleston BRD	Director/Board Member	55	12/08/2024

ValiRx Plc Share Price London S.E.

Stocks

GB00B23N9136

Biotechnology & Medical Research

Valuation : ValiRx Plc

Latest news : ValiRx Plc

Press Releases : ValiRx Plc

Managers and Directors : ValiRx Plc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-1.59%	-3.35%	+52.37%	+93.70%	6.95TCr
ARGENX SE	-1.34%	-0.75%	+48.21%	+91.86%	6.5TCr
WUXI BIOLOGICS (CAYMAN) INC.	+0.30%	-0.69%	+52.56%	+10.23%	2.65TCr
INSMED INCORPORATED	-2.35%	-5.75%	-12.90%	+448.54%	2.59TCr
BIONTECH SE	-8.37%	-12.43%	+2.08%	-16.71%	2.56TCr
PHARMAESSENTIA CORPORATION	-0.96%	+10.36%	+283.06%	+436.50%	2.02TCr
GENMAB A/S	-0.51%	+0.23%	+35.77%	-18.70%	2TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.91%	-4.37%	+13.28%	+535.19%	1.57TCr
EXELIXIS, INC.	-1.47%	+0.68%	+45.51%	+143.08%	1.35TCr
Average	-2.02%	-1.93%	+57.77%	+191.52%	3.13TCr
Weighted average by Cap.	-1.93%	-1.50%	+53.73%	+151.51%

	2024	2025
Net sales	0.05 0.07 0.06 0.05 0.09 6.45 0.09 0.65 0.25 3.26 0.25 0.25 10.8	0.03 0.04 0.04 0.03 0.06 4.07 0.06 0.41 0.16 2.05 0.16 0.16 6.8
Net income	-19.16L -25.97L -22.38L -20.99L -36.09L -25Cr -36.2L -2.49Cr -97.14L -13Cr -97.52L -95.4L -42Cr	-22.32L -30.27L -26.08L -24.45L -42.05L -29Cr -42.18L -2.9Cr -1.13Cr -15Cr -1.14Cr -1.11Cr -48Cr
Net Debt	-15.44L -20.94L -18.04L -16.92L -29.09L -20Cr -29.18L -2.01Cr -78.3L -10Cr -78.61L -76.9L -33Cr	-8L -10.71L -9L -9L -14.89L -10Cr -14.93L -1.03Cr -40.07L -5.17Cr -40.23L -39.35L -17Cr